Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
U649136-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$150.90
|
|
|
U649136-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$240.90
|
|
|
U649136-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$490.90
|
|
|
U649136-50mg
|
50mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$780.90
|
|
|
U649136-100mg
|
100mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,250.90
|
|
| Specifications & Purity | ≥99% |
|---|---|
| Biochemical and Physiological Mechanisms | UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also f |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD). In Vitro UCM-1306 (2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl; 1-10 μM) increases cAMP in a concentration-response manner with high potency (EC 50 =60 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo UCM-1306 (2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl; 5 mg/kg; p.o.; C57BL/6J mice) has good brain penetration and oral availability. Plasma concentration can be quantified for up to 8 h with T max at 0.5 h . UCM-1306 (1 mg/kg; ip) enhances cocaine-induced hyperlocomotion in adult mice . UCM-1306 (1 mg/kg; ip) helps consolidate long-term memory formation . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Adult C57BL/6J mice with cocaine-induced hyperactivity model Dosage: 1 mg/kg; cocaine (20 mg/kg, sc) Administration: Intraperitoneal injection Result: Increased cocaine-induced hyperlocomotion, suggesting an in vivo potentiation of DA action at the D1R. Animal Model: Adult C57BL/6J mice Dosage: 1 mg/kg Administration: Intraperitoneal injection Result: Increased memory trace in C57BL/6J mice. Form:Solid |
| Smiles | O=S(C1=CC=C(C2=C(OCF)C=CC=C2)C=C1)(C)=N |
|---|---|
| Molecular Weight | 279.33 |
| Solubility | DMSO : 50 mg/mL (179.00 mM; Need ultrasonic) |
|---|